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Abstract
To assess the intra-individual and inter-individuals biological variation and the effect of aging on lymphocyte T-cells subsets.
We assessed lymphocyte phenotypes (CD3+, CD4+, and CD8+ T-cells) in 89 HIV-1-infected and 88 uninfected white non-Hispanic
men every 6 months, to examine the biological variation for those measurements, and the average change in lymphocyte phenotype
over 34 years.
The markers showed significant intra-individuality in HIV-infected and uninfected individuals with index of individuality of <1.4. No
mean changes were seen over the 34 years, with the exception of percentage CD4+T-cells in HIV-uninfected individuals.
In the pre-HAART era, HIV-infected individuals experienced an increase in mean absolute CD3+ T-cell numbers (11.21cells/mL, P
= 0.02) and absolute CD8+ T-cell numbers (34.57cell/ml, P< .001), and in the percentage of CD8+ T-cells (1.45%, P< .001) per year
and a significant decrease in mean absolute CD4+ T-cell numbers (23.68cells/ml, P< .001) and in the percentage of CD4+ T-cells
(1.49%, P< .001) per year.
In the post-HAART era, no changes in mean levels were observed in absolute CD3+ T-cell count (P= .15) or percentage (P= .99).
Significant decreases were seen in mean count (8.56cells/ml, P< .001) and percentage (0.59%, P< .001) of CD8+ T-cells, and
increases in mean absolute count (10.72cells/ml, P< .001) and percentage (0.47%, P< .001) of CD4+ T-cells.
With the exception of CD4 (%), no average changes per year were seen in lymphocyte phenotype of HIV-uninfected men. The
results of coefficients of variation of intra and inter-individuals of this study can be useful for HIV-1 infection monitoring and in addition
the observation could be a useful guide for intra- and inter-individual coefficient variations, and establishing quality goal studies of
different blood biomarkers in healthy and other diseases.
Abbreviations: (CVG) = coefficient variation of inter-individual, CBC = complete blood count, CD = cluster of differentiation, CVI =
coefficient variation of Intra-individual, HAART = highly active antiretroviral therapy, HIV = human immunodeficiency virus, I.I. = index
of individuality, WBC = white blood cell.
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Analyte components of blood cells can fluctuate over the course
of an individual’s lifespan. Some of these variations are caused by
predicable biological cycles or rhythms that all individuals share,
while other sources of variation may be due to differences
between individuals.
Numerous factors can contribute to variations in blood
markers. Some of them are controllable (blood collection
technique) whereas other characteristics such as race, sex, and
age are not subject to manipulation. Biological factors are often
the most important source of variation over time for certain
analytes and marked changes can occur during the neonatal
period, childhood, puberty, menopause, and aging. In addition,
certain analytes have biological rhythms that can vary diurnally,
monthly, or seasonally.[1]
The interpretation of a patient’s test result using a laboratory’s
reference value is thus far the only valid tool available to
clinicians when the biological variability of the population
reference values and of the target population are comparable.[2]
Certain analytes display a high degree of inter-individual
variation as a result of widely ranging homeostatic set points,
even within a population that is considered “healthy.” This
marked individuality makes it difficult to construct a single
reference interval that represents a “healthy” range for all
individuals since many individuals will present with values that
are highly unique for them but still lie outside or inside
population-based reference value ranges.[3–10]
Comparing a patient’s test result with a value from a published
reference population, it is possible to detect clinically relevant
changes in blood lymphocyte subsets, which can be useful for
prevention, diagnosis, prognosis, and treatment of various
diseases. Repeated measurements of an analyte obtained by a
longitudinal study of an individual may be preferable to use than
a single measure in conjunction with population-based refer-
ences. In the case of repeat measures, the patients have their own
reference or baseline for each biomarker and changes between
consecutive tests may be indicative of illness.[2]
Between 1979 and 1981, the appearance of opportunistic
infections and Kaposi sarcoma in previously healthy gay men in
the United States was documented as an acquired cellular
immunodeficiency syndrome (AIDS) and the first human
disease caused by an unknown agent with a significant loss of
CD4+ T-cells.[11–12]
Cohort studies such as the MACS, WITS (Women and Infant
Transmission Study), WIHS (Women’s Interagency Health Study)
and others, which investigated the natural history of human
immunodeficiency type 1 (HIV-1) infection, discovered the utility of
quantifying CD4+ T-cell numbers as a predictor of clinical risk in
HIV-1 infected individuals, independent of treatment,[13] and as a
prognostic tool for HIV-1 disease progression.[14–15] In addition to
CD4+ T-cell depletion, lymphoid atrophy and immune activation,
such as elevated expression of CD38 on CD8+ T-cells, are the other
major characteristics ofHIV-1 disease.[16] In the early stages ofHIV-
1 infection,HIVRNAlevel has highprognostic value and in the later
stages of disease, CD4+ T-cell count is a predictor of AIDS.[14,17]
Knowledge of the intra- and inter-individual variability are
essential for the longitudinal assessment of blood biomarkers.
Thus, the aim of our study was to assess the biological variation
and the effect of aging on T-cells subsets (CD3+, CD4+ and CD8+
T-cell) over a period of 34 years. We accomplished this by
examining the biological coefficient of variation of intra-2individual (CVI) and inter-individuals (CVG) for immunophe-
notyped T-cell subsets in a population of HIV-1 infected and
HIV-1 uninfected white non-Hispanic males. The biological
variation and magnitude of changes in CD3+ T-cells, CD4+ T-
cells, and CD8+ T-cells (percentages and absolute counts) were
investigated in this study.2. Material and methods
2.1. Study participants
We investigated routine lymphocyte phenotype in 2 groups (HIV-
1 uninfected and HIV-1 infected individuals). The HIV-1
uninfected group consisted of 88 individuals with no diagnosis
of major illness, such as cancer, hepatitis B or C infection, kidney
disease or diabetes, all of whom were documented to be HIV-1
sero-negative at every study visit (6-month intervals) over the
course of 34 years. The HIV-1 infected group was 89 individuals,
of whom 2 participants did not receive any medication for HIV-1
until recent visits (1 of the participants started medication on
February 2017), 19 received 1 to 3 different anti-viral
medications, 30 received 4 to 6, 26 received 7 to 9, 9 received
10 to 12 and 3 received 13 to 15 in the period of 34 years.
These individuals were men who have sex with men (MSM)
participating in the Los Angeles (LA) Multicenter AIDS Cohort
Study (MACS) and self-report as white, non-Hispanic[18] and for
minimizing of inter-racial variability, other ethnicity were excluded.
Theageof theparticipants in theHIV-uninfectedgroupat the startof
the study (1984–1985) ranged from 22 to 49 years old with a mean
of 33 andmedianof 32years old. Theywere 51 to81years old at the
last recorded visit through December 2017. The age of participants
in the HIV-infected group at the start of the study (1984–1985)
ranged from22 to56yearsoldwithameanof31.5andmedianof31
years of age; they were 55 to 84 years old at the last recorded visit
through December 2017. The average length of time between a
participant’sfirst and last visit was 34 years. The institutional review
board for human studies at UCLA approved the protocols.2.2. Blood collection and laboratory assays
After informed consent, blood samples were obtained every
6 months, between 8:00 AM to 12:00 PM, from each individual
into two of 4ml (Becton Dickinson VACUTAINER Systems,
New Jersey) tubes with EDTA anticoagulant for complete blood
count (CBC) and flow cytometry analysis.
Complete blood count (CBC) assessments with 3-part
differential and platelet count were performed with automated
hematology analyzers by CLIA-certified clinical reference
laboratories.[19] The absolute count of a lymphocyte phenotype
using white blood cell (WBC) count and lymphocyte percentage
from the CBC report of each individual was calculated as follow:
T cell count ¼ ðWBC=mLÞ  ðlymphocyte%=100%Þ
ðT cell%=100%Þ:
e:g:6000WBC=mL; Lymphocyte : 50%;
CD4þ T cell : 25%CD4þ T cell ¼ ð6000 cells=mLÞ
ð50%=100%Þ  ð25%=100%Þ ¼ 750 cells=mL:
Lymphocyte Immunophenotyping performed by the Los
Angeles MACS flow cytometry laboratory which participates
in the Immunology Quality Assessment (IQA) program of
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System (April 1984 to April 1991), Becton Dickinson (BD)
FACScan Flow Cytometry System (May 1991 to October 2004),
and BD FACSCalibur Flow Cytometry System (October 2004 to
present). Flow cytometry data were analyzed by utilizing
CellquestR software (BDIS).
Throughout our study due to innovation in the field of
laboratory instruments and automation technology, our labora-
tory used 3 different Flow cytometers. Each time the tests for
accuracy, and precision were performed concurrently using the
same samples by both instruments and the specifications set by
manufacturer establishing the comparability overtime of the
measurements.2.3. Staining methods
EDTA Anticoagulated blood was collected by venipuncture and
held at room temperature until staining, which was performed
within 24hours of collection. An ammonium chloride-lysed
whole blood method (LW) and a Lyse no wash (LNW) method
were performed. The detailed procedure can be found in
published literature,[20] briefly:
Two-color Lyse wash staining: (1984 to March 1996) 50ml of
undiluted whole blood was added to 12  75mm tubes
containing 20ml of undiluted BD Simultest CD45PE/CD14
FITC CD3PE/CD4FITC, and CD3PE/CD8 FITC antibodies (BD
BioScience), the tubes vortexed gently, and then incubated for 20
minutes at room temperature in the dark. After incubation, the
cells were lysed twice by addition 1ml of 1x freshly made
ammonium chloride-lysing solution into[20] the tubes and tubes
were incubated for 5 and 3 minutes for the first and second
washes respectively. At the end of each incubation, the tubes were
centrifuged at 200g for 5 minutes and the supernatants removed
without disturbing the cell pellets. After the final centrifugation,
the pellet was re-suspended in 500ml staining buffer (1 x PBS, 2%
newborn calf serum, 1% Sodium azide).
Lyse NoWash staining procedure: (April 1996 to present time)
50ml of undiluted whole blood was added to 12  75mm tubes
containing 20ml of undiluted BD Tritest CD3FITC/CD4PE/
CD45 PerCP and BD Tritest CD3FITC/CD8PE/CD45PerCP
antibodies (BD BioScience), the tubes vortexed gently, and then
incubated for 15 minutes at room temperature in the dark. After
the incubation, 450ml 1x BD FACSLyse lysing solution was
added followed by another vortexing and 15 minutes incubation.2.4. Statistical analysis
Descriptive statistics of the lymphocyte immunophenotyping
markers that comprised the CD3+, CD4+, and CD8+ T-cells
(absolute cell counts and percentage) were generated for mean
and absolute ranges of intra- and inter-individuals. Linear trends
were estimated using generalized estimating equations (GEE).We
added a spline knot at visit 23 (1995–1996) to create a piece-wise
regression function for calculating the average change. The spline
function accommodated the comparison of the Pre-HAART and
post-HAART period for HIV-1 infected individuals.
The nested analysis of variance was used for calculation of
coefficients of variation of intra-individual (CVI) and inter-
individuals (CVG). CVI and CVG were calculated according to
the approach used byHarris and Boyd.[21] Since the precision of the
measurement tool was high, and the reliability of replicate measures
was not of interest, we omitted measures of analytic variation from3these calculations. Index of Individuality (II) is the simple ratio of the
2 biological components of variation: intra-individual to inter-
individuals and is calculatedusing the formulaCVI/CVG.
[1]The II, as
defined by Harris[22] assesses the usefulness of population-based
reference values for interpretation of laboratory tests. If the II of a
given analyte is greater than 1.4, then population-based intervals are
useful; an II below 1.4 indicates decreased utility of population-
based reference intervals. Analytes with an II less than 0.6
demonstrate (paradoxically) a high degree of individuality, making
individual-based reference intervals more useful.
All analyses were performed using SAS version 9.4 (SAS
Institute, Cary, NC). Graphs were created using SIGMAPlot
software version 14 (Jandel Scientific, San Rafael, CA 2018).
3. Results
3.1. Components of biological variation
The CVI, CVG, and index of individuality (II), along with the
overall means (number and percentage) of T-cell lymphocyte
phenotypes (CD3, CD4, CD8), for 1 (0–2 visits), 10 (0–20 visits),
20 (0–40 visits) and 34 (0–67 visits) years of follow-up for HIV-1
uninfected and infected individuals are presented in Table 1. As
described in the methods, it is considered appropriate to use
population-based reference ranges when the II of a given analyte
is greater than 1.4. The indices of individuality in our study for
the routine T-cell markers were less than 1.4 for all time intervals
after year 1.3.2. Mean and minimum-maximum T-cell values
The means, absolute count and percentage ranges (minimum–
maximum values) over all study visits for each HIV-1 uninfected
individual (n=88) and infected individual (n=89) are shown
graphically for CD3+ T-cells, CD4+ T-cells, and CD8+ T-cells in
Figure 1 and Figure 2, respectively. Visual inspection of these
figures shows that the mean values of the same analyte can differ
greatly between individuals and this is seen in both the HIV-1
uninfected and infected groups.
The mean values of absolute counts and percentage of CD3+ T-
cells for HIV-1 uninfected and infected individuals almost all lie
within the reference limits (Fig. 1, 2 A1 and A2). Similarly, most
mean values of absolute number and percentage of CD4+ T-cells
and CD8+ T-cells for HIV-1 uninfected individuals lie within the
reference interval. Looking at the data ranges, much of the data
also fall within the reference intervals. However, there are
definitely HIV-1 uninfected individuals with some data points
that fall outside 1 or both of the upper and lower reference limits,
for example absolute numbers of CD3+, CD4+, andCD8+ T-cells
of participant of 48 (Fig. 1 A1, B1, C1).
28 (31%) out of 89 mean absolute counts of CD4+ T-cell data
for HIV-1 infected individuals fell outside of the lower reference
limit (LRL). Interestingly, we observed that 71 (79.8%) out of 89
mean percentages of CD4+ T-cell data fell outside the LRL (Fig. 2,
B1 and B2). 67 (75%) out of 89mean absolute counts of CD8+ T-
cell data were outside the upper reference limit (URL) and for the
percentage data, 85 mean percentages of CD8+ T-cell fell outside
of the URL (Fig. 2, C1 and C2).3.3. Magnitude of T-cell changes
In order to evaluate direction and magnitude of changes in each
marker from baseline (0 visit) over the 34 years follow-up,
Table 1
Mean values, intra-individual (CVI) and inter-individuals (CVG) variation, and index of individuality (II) for each T-cell parameter for 88 HIV-
uninfected & 89 HIV-infected individuals at intervals from 1 to 34 years.
Length (year): 1 10 20 34
Sero-status: HIV HIV+ HIV HIV+ HIV HIV+ HIV HIV+
CD3+ T-Cell
Mean (cell/mL) 1495 1524 1465 1570 1468 1624 1463 1629
CVI (%) 21.2 19.2 19.2 23.7 18.4 26.2 18.3 26.2
CVG (%) 23.8 20.6 22.4 23.6 21.7 23.2 21.7 24.1
II 0.89 0.93 0.86 1.00 0.85 1.13 0.85 1.09
CD3+ T-Cell
Mean (%) 74.5 80.2 72.3 79.5 73.3 78.8 73.9 78.2
CVI (%) 7.1 5.4 6.3 6.2 5.6 7.0 5.6 7.3
CVG (%) 7.6 7.7 7.5 6.8 7.9 7.1 8.4 6.9
II 0.93 0.70 0.84 0.91 0.72 0.99 0.68 1.06
CD4+ T-Cell
Mean (cell/mL) 893 684 916 583 916 544 918 559
CVI (%) 19.5 19.6 19.0 29.0 18.4 35.3 18.6 35.0
CVG (%) 27.7 26.8 25.4 28.2 23.6 29.9 23.2 29.5
II 0.77 0.73 0.75 1.03 0.78 1.18 0.80 1.19
CD4+ T-Cell
Mean (%) 44.6 36.1 45.3 29.9 45.9 26.6 46.6 27.0
CVI (%) 9.0 13.3 9.2 23.5 8.6 28.9 9.0 26.9
CVG (%) 13.0 18.8 11.2 19.9 11.5 21.8 12.4 20.8
II 0.69 0.71 0.82 1.18 0.75 1.32 0.73 1.39
CD8+ T-Cell
Mean (Cell/mL) 596 786 573 955 565 1045 558 1041
CVI (%) 26.8 24.1 25.4 32.6 24.8 33.0 25.3 32.4
CVG (%) 28.2 26.2 26.8 29.5 28.8 27.8 32.2 29.0
II 0.95 0.92 0.95 1.11 0.86 1.19 0.78 1.12
CD8+ T-Cell
Mean (%) 29.6 41.2 28.3 48.0 28.1 50.6 28.0 49.7
CVI (%) 15.2 11.2 15.1 17.6 14.3 17.1 14.6 16.7
CVG (%) 18.4 18.6 18.2 14.4 20.1 14.5 23.6 14.7
II 0.82 0.60 0.83 1.22 0.71 1.18 0.62 1.14
Figure 1. CD3+, CD4+, and CD8+ T-cell of HIV-1 uninfected individual. Mean (filled circle) and absolute range (error bars) for each HIV-1 uninfected individual (n=
88) over 34 years follow-up, for absolute (A1, B1, and C1) count and percentage (A2, B2, and C2) of CD3+ T-cell, CD4+ T-cell, and CD8+ T-cell; each pair of vertical
dashed lines represents the lower reference limit (LRL, left side) and upper reference limit (URL, right side), as described in the methods.
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Figure 2. CD3+, CD4+, and CD8+ T-cell of HIV-1 infected individual. Mean (filled circle) and absolute range (error bars) for each HIV-1infected individuals (n=89)
over 34 years follow-up, for absolute count (A1, B1,and C1) and percentage (A2, B2 and C2) of CD3+ T-cell, CD4+ T-cell, and CD8+ T-cell; each pair of vertical
dashed lines represents the lower reference limit (LRL, left side) and upper reference limit (URL, right side), as described in the methods.
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estimate the average change per year in values and corresponding
P values (Table 2). The longitudinal analysis over the course of 34
years, HIV-1 uninfected group showed a statistically significant
increase (0.1%/year) only for percentage of CD4+ T-cells and no
changes for other T-cell phenotypes in the HIV-1 uninfected
individuals (Table 2).
The HIV-1 infected group in the pre-HAART era, from
baseline (visit 0) to visit 23 (1996), a significant decrease was
observed in HIV-1 infected individuals for both absolute countTable 2
Average change per year in lymphocyte phenotype over 34 years follo
active antiretroviral therapy (HAART).
Marker (unit)
HIV-1 uninfected
Change
∗
Significance
level
HIV-1 infe
Pre-HAART C
CD3+ T- Cell/ml 0.29 ↔ P= .82 11.21↑
CD3+ T-Cell (%) 0.05↔ P= .08 0.13↔
CD4+ T-Cell /ml 0.87↔ P= .33 23.68↓
CD4+ T-Cell (%) 0.11↑ P< .001 1.49↓
CD8+ T-Cell /ml 1.07↔ P= .19 34.57↑
CD8+ T-Cell (%) 0.04↔ P= .18 1.45↑
∗
Average mean changes in marker values per year from baseline; ↑increase; ↓decrease; ↔ no signifi
† Average mean changes in marker values per year from visit 24 or 1996.
5(23.7cells/year) and percentage (1.5%/year) of CD4+ T-cells.
Increases in values were seen for both absolute number (34.6
cells/year) and percentage (1.5%/year) of CD8+ T-cells during the
same time period. A significant increase of 11.2cells/year was
seen for CD3+ T-cells, while no change was seen for CD3+ T-cell
percentage per year (Table 2). In the post-HAART era, visit 24 to
visit 67 (1996 -2018), a significant increasewas observed for both
absolute count (10.7cells/year) and percentage (0.5%/year) of
CD4+ T-cells. Significant decreases were seen for both absolute
number (8.6cells/year) and percentage (0.6%/year) of CD8+w-up of HIV-1 uninfected and infected men receiving HIV-1 highly
cted
hange
∗
Significance
level
HIV-1 infected
Post- HAART Change†
Significance
level
P= .02 0.87↔ P= .15
P= .11 0.14↔ P= .99
P< .001 10.72↑ P< .001
P< . 001 0.47↑ P< .001
P< . 001 8.56↓ P< .001
P< . 001 0.59↓ P< .001
cant change.
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subset (Table 2).4. Discussion
Flow cytometry has advanced from a limited research tool in the
1980s to a routine laboratory technique used today that, in
addition to determining lymphocyte phenotype subsets, can be
used to provide useful diagnostic and prognostic information
about HIV-1 infection, leukemia, lymphoma, and other diseases.
Additionally, serial or longitudinal testing of patients’ blood
lymphocyte phenotype can assist physicians in detecting changes
in markers over time and during the natural course of a disease
aiding in treatment and preventative decisions.
For 34 years, we have longitudinally examined the mean values
and biological variation of CD3+, CD4+, and CD8+ T-cells of
lymphocytes circulating in the blood of HIV-1 uninfected and
infected individuals in a relatively homogeneous cohort of men as
they aged. We assessed the intra-individual coefficient of
variation (CVI) and the inter-individual coefficient of variation
(CVG) of absolute count and percentage of the lymphocyte
phenotype parameters for 1, 10, 20, and 34 years of follow-up
(Table 1).
The mean data of HIV-1 uninfected individuals during 1 year
follow-up in our study for percentage and absolute counts of
CD3+ T-cells (75%, 1495cells/ml), CD4+ T-cells (45%, 893cells/
ml), and CD8+ T-cells (30%, 596cells/ml) were consistent with the
published studies of Valiathan et al. (78%, 1514cells/ml for CD3+
T-cells, 47%, 921cells/ml for CD4+cells, and 28%, 562cells/ml
for CD8+ T-cells),[23] Tollerud et al (75%, 1582cells/ml for CD3+
T-cells, 49%, 1036cells/ml for CD4+T-cells, and 28%, 595cell/ml
for CD8+ T-cells),[24] and Reichert et al (73% for CD3+ T-cell,
43% for CD4+T-cells, and 33% for CD8+ T-cells).[25] Despite the
testing only males, our data reiterated the technical reliability,
and biological stability of the CD3+, CD4+, and CD8+ T-cells of
lymphocytes circulating in the blood of the above published
studies.
In 1994, Hughes et al evaluated the magnitude of the CVI of
CD4+ T-cell count in asymptomatic HIV-1 infected individuals (2
year follow-up) for 3 groups based on their absolute CD4 counts
of 200, 500, and 800cells/ml. The CVI of the study were 35%,
25%, and 19%, respectively[26] and the third group has some
similarity with CVI of CD4
+ T-cells of HIV-1 infected individuals
our study (19.6% and mean CD4+ T-cells of 684cells/ml).
The mean and ranges of lymphocyte phenotype are graphically
presented in Figure 1 and Figure 2 for HIV-1 uninfected andHIV-
1 infected individuals, respectively. The mean absolute counts
and percentage values of CD3+, CD4+, and CD8+ T-cells were
relatively variable and yet, for the HIV-1 uninfected individuals, a
majority of data fell within the conventional reference interval
value and any illnesses or problems they might have had were not
caught using the lymphocyte phenotype conventional reference
values. In those circumstances, using the patient’s own reference
or baseline for the lymphocyte subsets may be a useful tool for
follow-up.[4]
In HIV-1 infected individuals, the absolute counts and
percentage data of CD3+ T-cells are varied and unusual but
still fall within the reference interval value; this may be due to
homeostatic compensation of mostly of CD8+ T-cell changes in
HIV-1 infected individuals.
Using CD4+ or CD8+ T-cell percentage data (Supplementary
Fig. 1C and E, http://links.lww.com/MD/D285) along with the6absolute counts of CD4+ or CD8+ T-cells (Supplementary Fig. 1
D and F, http://links.lww.com/MD/D285) as a laboratory tool
can add more prognostic value compared to using either absolute
values or percentages alone. This is particularly evident when
dealing with CD4+ T-cell counts of HIV-1 infected individuals
(Supplementary Fig. 2 A and B, http://links.lww.com/MD/D285).
The direction and magnitude of changes for each lymphocyte
phenotype marker from baseline (0 visit) over the 34 years
follow-up, reflecting, among other factors, the aging of the
individuals was also studied for HIV-1 uninfected and infected
individuals. With the exception of the percentage of CD4+ T-cell
increase per year (P< .001), there were no significant average
changes per year for absolute counts and percentage of CD3+ T-
cells, CD8+ T-cells, and absolute count of CD4+ T-cells over 34
years for HIV-1 uninfected individuals (Table 2) (Supplementary
Fig. 1, http://links.lww.com/MD/D285).
HIV-1 infected individuals showed an interesting pattern of a
deflection point (downwards) for percentage and absolute counts
of CD4+ T-cells and inflection point (upwards) for percentage and
absolute counts of CD8+ T-cells at time point of 12 years (1995–
1996 or HAART era) of 34 years follow-up. The period between
baseline to 12 years coincided with the pre-HAART era and the
time of 1996 to 2017was the post- HAART era of HIV-1 infected
individuals.
CD4+ T-cells in HIV-1 infected individuals, the data show a
significant average decrease of 23.68 absolute cell numbers and
1.49% per year from the baseline mean to 12 year follow-up
(deflection point) and a subsequent and significant average
increase of 10.72 cells and 0.47% frommean value of the 12-year
time point to 34 years follow-up (post-HAART). The reverse was
seen for CD8+ T-cells, with a significant average increase of 34.57
cells and 1.45% per year from the baseline mean to 12 year
follow-up and a significant average decrease of 8.56 cells and
0.59% per year from mean value at the 12-year time point
(inflection point) to 34 years follow-up (post-HAART) (Table 2
and supplementary Fig. 1, http://links.lww.com/MD/D285).
TwoHIV-1 infected individuals, # 61 and # 12, 1 of whomwas
HLA-B57+ (Individual # 61) had CD4+ T-cell counts of 890 and
738 cells at baseline, respectively. Both were long-term non-
progressors (LTNP’s) maintaining a favorable course of
asymptomatic infection with high CD4+T-cells and low viral
load.[27–28] They did not receive any anti-HIV-1medication in the
course of the 34 years follow-up (individual # 61 has taken
medication since February 2017), and did not follow the same
pattern (deflection or inflection) as the rest of the HIV-1 infected
group, showing instead a constant slow decrease in percentage
and absolute counts of CD4+ T-cells (Fig. 3).
5. Conclusion
The lymphocyte phenotypes (CD3, CD4, CD8) in HIV-1
uninfected individuals show high individuality but with a
majority of values falling within the reference range and for
those individuals, knowledge of baseline levels will be a helpful
tool for follow-up. Thirty-four years of follow-up demonstrate
that the mean values of CVI are higher, relative to CVG, values in
HIV-1 infected individuals as compared to HIV-1 uninfected
individuals. CD4+ T-cell percentage value, along with the
absolute counts of CD4+ T-cells, adds more prognostic value
compared to using either absolute values or percentages alone
when dealing with CD4+ T-cell counts of HIV-1 infected
individuals. With the exception of CD4 (%), no average changes
Figure 3. Absolute count changes of CD4+ T-cells. Filled circles symbolize HIV-1 infected individual # 61 (HLA-B57+) with a baseline CD4+ T-cell count of 890cell/
ml who started HIV-1 medication on February 2017. Open circles symbolize HIV-1 infected individual # 12 with a baseline CD4+ T-cell count of 738cell/ml followed
for total of 68 visit (34 years). The dashed red line represents the CD4+ T-cell limit for an AIDS diagnosis.
Aziz et al. Medicine (2019) 98:41 www.md-journal.comper year were seen in lymphocyte phenotype subsets of HIV-1
uninfected men and the data were stable over the course of 34
years. These results can be useful for informing prognosis or
outcome of therapy. In addition the observations could be a
useful guide for intra- and inter-individual coefficient variations,
and establishing quality goal studies of different blood
biomarkers in healthy and other diseases.Acknowledgments
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